£5 off at Well Pharmacy when you spend £15
HERE'S an amazing offer for readers to get £5 off at Well Pharmacy when you spend £15 at any of over 650 Well Pharmacy branches across the UK.
Why not stock up on all your summer essentials, like sunscreen, insect repellent and hay fever medication? In fact, the offer covers most things you could find in your friendly local Well Pharmacy.
Well Pharmacy is the largest independent pharmacy chain in the country. As well as making sure you get your NHS prescriptions quickly and easily, their expert pharmacists are on hand to give you advice and support with your health needs and can help you stock up on those summer health and beauty essentials
To claim your £5 voucher , pick up your Daily Mirror or Sunday Mirror between Wednesday, July 16 and Sunday, July 20, 2025 to find your printed voucher inside and present it at your local Well Pharmacy.
Alternatively complete the form below and you will receive your digital voucher direct to your email. (do check your spam/junk folder).
Voucher valid from Wednesday 16 th July until close of stores on Monday 4th August.
If you cannot see the form above CLICK HERE
As well as helping you with your prescriptions, Well Pharmacy also offers a broad selection of NHS and private services to help you stay proactive with your healthcare. They can save you waiting for a GP appointment for advice and treatment for a range of minor conditions through the Pharmacy First service (Common Ailment Service in Wales). The conditions include infected insect bites, impetigo, shingles, sinusitis, sore throats, earache and urinary tract infections in women. No appointment needed, just ask at the counter. To find a list of services in your local Well pharmacy or online, visit well.co.uk
To find your nearest store, visit well.co.uk. Terms and conditions: Offer valid until Monday, August 4th, 2025, in Well Pharmacy stores only, excludes online. Minimum spend of £15 applies. One voucher per transaction. Not to be used with any other promotion or voucher. Only original vouchers are valid. No photocopies. Cannot be used against any purchase of prescriptions, vaccinations, paid for services or baby milk. Coupon not transferable. No change given.
Well Pharmacy
As well as a large range of healthcare products, Well Pharmacy also offers a broad selection of NHS and private services to help you stay proactive with your healthcare. They can take the hassle out of prescriptions by nominating your local Well Pharmacy or their online service to receive your medication to click and collect, or to be delivered straight to your door in discreet packaging.
Well Pharmacy can even save you waiting for a GP appointment for advice and treatment for a range of minor conditions through the Pharmacy First service. The conditions include infected insect bites, impetigo, shingles, sinusitis, sore throats, and urinary tract infections in women. No appointment needed, just ask at the counter.
From the 22nd July, all Well pharmacies can help with weight loss for those who have struggled to lose weight previously. A pharmacist will guide you through each month with a recommended weight loss product and healthy lifestyle advice tailored to you. Patients can lose up to 20% of their starting weight with selected weight loss products.
If you are unable to get into your local branch and have previously struggled to lose weight you can also access this service online via https://well.co.uk/weight-management
Well Pharmacy have helped thousands of patients to lose weight already, such as Sandra who in her Trustpilot review of the service says, 'A fantastic service. Polite and courteous staff. Life changing opportunity to lose weight.'
For those over 40 in England, you can receive free NHS blood pressure checks at your chosen Well Pharmacy. Around 1 in 3 adults in the UK have high blood pressure and the chance of developing it increases with age. If left untreated, hypertension, which often has no symptoms, can lead to serious heart and circulatory diseases such as heart attack and stroke. Pop to your local Well Pharmacy and ask for a free blood pressure check with a member of the team who will be happy to help you in their private consultation room.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
12 minutes ago
- BBC News
More weight-loss drugs offered in type 2 diabetes care shake-up
Treatment for millions of people with type 2 diabetes should be more personalised, with greater access to newer medicines, including weight-loss drugs, the healthcare assessment body for England, Wales and Northern Ireland has calls the move "the biggest shake-up" in type 2 diabetes care in a more people the new drugs will prevent complications such as heart disease, strokes and kidney damage, reduce costs to the NHS and potentially save lives, the National Institute for Health and Care Excellence (NICE) says. Around 4.6 million people in the UK are diagnosed with diabetes - of these 90% have type 2, with another 1.3 million likely to be undiagnosed. Having type 2 diabetes means there is too much glucose or sugar in the blood. This makes strokes, heart attacks, heart failure and other health conditions much more of a risk. It is now so common that 10% of the NHS budget goes towards treating which produces guidance for the NHS on how to give patients the best care, recommends a move away from a "one size fits all" approach and towards more personalised is calling for newer diabetes medicines called SGLT-2 inhibitors, which protect the heart and kidneys as well as lowering blood sugar levels, to become the first-choice treatment for all diabetes patients. Around 2.3 million people will be eligible for these 22,000 lives could be saved if 90% of all diabetes patients were prescribed them, NICE says, but access is not equal across the UK. There is evidence that women, older people and black people are less likely to be prescribed them."There is some urgency to find ways to increase the uptake of SGLT-2 inhibitors because if we were to achieve perfect uptake, the nation would be significantly healthier," said Dr Waqaar Shah, chair of the guideline one in five people with type 2 diabetes and cardiovascular disease are currently prescribed the the tablets to more people would particularly benefit those living in poorer areas and ethnic minorities, NICE says. Under the guidance, which is still at a draft stage and needs to go through a consultation, around 750,000 more people with type 2 diabetes will be offered GLP-1 agonists such as semaglutide and liraglutide, which have become very popular as the drugs contained in weight-loss with cardiovascular disease and some who develop type 2 before they are 40 are the groups recommended to be offered drugs can be used both to lower blood sugar levels and to support some people with weight Jonathan Benger, deputy chief executive and chief medical officer at NICE, said the updated guidance was "a significant evolution" in type 2 diabetes treatment which could help prevent heart attacks, strokes and other serious complications before they happen."This guidance means more people will be offered medicines, where it is right to do so, to reduce their future risk of ill health," he guidelines are part of a long-term plan by the NHS in England to reduce health inequalities and focus on preventing ill health in the first charity Diabetes UK said the announcement propelled type 2 diabetes treatments "into the 21st century"."These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes," said Douglas Twenefour, head of clinical at the charity.
The Independent
2 hours ago
- The Independent
At-home hepatitis C test identifies hundreds with silent but deadly virus
The NHS has identified 225 people with a silent but deadly virus as part of a national drive to stamp out the disease and uncover more victims of the infected blood scandal. The significant discovery was made after more than 100,000 at-home hepatitis C tests were requested since the service's launch in May 2023, including 15,463 in the week after the Infected Blood Inquiry published its final report in May 2024. Hepatitis C - known as a 'silent killer' - is a virus that is passed on through blood-to-blood contact and infects the liver. Some people can live with the virus for many years before realising that they are infected, but the delay in diagnosis can lead to irreparable liver damage, including scarring and cancer. If people test positive, they can often be treated by taking antiviral tablets to fight off the virus for several weeks or offered a test to see whether any damage has been caused to the liver. Health officials said that 105,998 people have ordered an at-home NHS hepatitis C test online since the service was launched in 2023. Among those diagnosed under the NHS scheme so far, NHS England said that seven in 10 are from deprived communities. The most common risk factors reported by positive cases include injecting drug use, sharing needles and other drug paraphernalia and a history of prison. It is understood that only a very small number identified after ordering a test online had a positive result after receiving contaminated blood. In May this year, NHS England also launched a system which means that people of a certain age who newly register with GP practices in England will be asked if they had a blood transfusion prior to 1996 in a bid to find more victims of the infected blood scandal. The Infected Blood Inquiry, which examined the scandal in depth, recommended that the health service should work to 'find the undiagnosed'. More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. And more than 3,000 people have died as a result, while survivors are living with lifelong health implications. Professor Meghana Pandit, NHS national medical director, said 'We want to make it easier for people to access care before hidden viruses like hepatitis C cause people serious harm. 'The home testing service is available to everyone, and through targeted outreach to people at higher risk we are helping thousands avoid serious illness and reducing health inequalities in the process. 'If you or someone you know might be at risk, order a free and confidential test today via the NHS hepatitis C testing website – it could save your life.' Early symptoms of hepatitis C NHS Sema Mandal, deputy director for blood safety at UK Health Security Agency, said: 'Our data shows that the number of people with hepatitis C in England is continuing to fall, thanks to more people getting tested and taking treatment that clears the virus. 'I'm delighted to hear that 100,000 of the free self-testing kits have already been ordered via NHS online and this should further help us defeat this disease.' Rachel Halford, chief executive of The Hepatitis C Trust, said: 'Reaching 100,000 home tests is an incredible milestone as we push closer towards the elimination of hepatitis C. 'This option of home testing allows people with any concerns to get a free, confidential test without the need to attend a clinic. For many hesitant to access health services, this can act as a lifeline. 'While injecting drug use remains a key risk factor, it is equally important to remember those affected by the infected blood scandal – the most devastating treatment disaster in the history of the NHS. 'If you received a blood transfusion or blood products before 1996, we strongly encourage you to order a test. Even for peace of mind alone, it could be invaluable. Today's treatments are highly effective, simple to take, and come with minimal side effects.'
Western Telegraph
2 hours ago
- Western Telegraph
Type 2 diabetes patients set for major shake-up in care
The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
